Beranda › Kanker Paru Non-Sel Kecil › Florida › Fort Lauderdale
Uji klinis Kanker Paru Non-Sel Kecil di Fort Lauderdale, FL
12 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Fort Lauderdale (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Holy Cross Hospital, Fort Lauderdale
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156), Fort Lauderdale
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Helios Clinical Research, Fort Lauderdale
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- The Oncology Institute of Hope and Innovation 1, Fort Lauderdale
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Menerima pesertaFase 2
- Holy Cross Hospital, Fort Lauderdale
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Research Site, Fort Lauderdale
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Sites, Fort Lauderdale
- Clinical Study Site, Fort Lauderdale
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Holy Cross Hospital, Fort Lauderdale
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Menerima pesertaFase 3
- Broward Health, Fort Lauderdale
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Menerima pesertaFase 3
- Holy Cross Hospital, Fort Lauderdale
- The Oncology Institute of Hope and Innovation, Fort Lauderdale
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Menerima pesertaFase 2
- Helios Clinical Research, Fort Lauderdale
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Menerima pesertaFase 1/2
- Holy Cross Hospital (site 213), Fort Lauderdale
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Fort Lauderdale
- Kanker (semua jenis)7 studi
- Kanker Paru7 studi
- Gagal Jantung6 studi
- Degenerasi Makula5 studi
- Kanker Ovarium4 studi
- Kanker Payudara4 studi
- Mieloma Multipel3 studi
- Kanker Darah3 studi
- Penyakit Ginjal Kronis3 studi
- Penyakit Kardiovaskular3 studi
- Kanker Kolon3 studi
- Kanker Kolorektal3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.